Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing

CRISPR-Cas gene editing has revolutionized experimental molecular biology over the past decade and holds great promise for the treatment of human genetic diseases. Here we review the development of CRISPR-Cas9/Cas12/Cas13 nucleases, DNA base editors, prime editors, and RNA base editors, focusing on...

Descripción completa

Detalles Bibliográficos
Autores principales: Tao, Jianli, Bauer, Daniel E., Chiarle, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9838544/
https://www.ncbi.nlm.nih.gov/pubmed/36639728
http://dx.doi.org/10.1038/s41467-023-35886-6
_version_ 1784869311594102784
author Tao, Jianli
Bauer, Daniel E.
Chiarle, Roberto
author_facet Tao, Jianli
Bauer, Daniel E.
Chiarle, Roberto
author_sort Tao, Jianli
collection PubMed
description CRISPR-Cas gene editing has revolutionized experimental molecular biology over the past decade and holds great promise for the treatment of human genetic diseases. Here we review the development of CRISPR-Cas9/Cas12/Cas13 nucleases, DNA base editors, prime editors, and RNA base editors, focusing on the assessment and improvement of their editing precision and safety, pushing the limit of editing specificity and efficiency. We summarize the capabilities and limitations of each CRISPR tool from DNA editing to RNA editing, and highlight the opportunities for future improvements and applications in basic research, as well as the therapeutic and clinical considerations for their use in patients.
format Online
Article
Text
id pubmed-9838544
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-98385442023-01-15 Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing Tao, Jianli Bauer, Daniel E. Chiarle, Roberto Nat Commun Review Article CRISPR-Cas gene editing has revolutionized experimental molecular biology over the past decade and holds great promise for the treatment of human genetic diseases. Here we review the development of CRISPR-Cas9/Cas12/Cas13 nucleases, DNA base editors, prime editors, and RNA base editors, focusing on the assessment and improvement of their editing precision and safety, pushing the limit of editing specificity and efficiency. We summarize the capabilities and limitations of each CRISPR tool from DNA editing to RNA editing, and highlight the opportunities for future improvements and applications in basic research, as well as the therapeutic and clinical considerations for their use in patients. Nature Publishing Group UK 2023-01-13 /pmc/articles/PMC9838544/ /pubmed/36639728 http://dx.doi.org/10.1038/s41467-023-35886-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Article
Tao, Jianli
Bauer, Daniel E.
Chiarle, Roberto
Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing
title Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing
title_full Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing
title_fullStr Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing
title_full_unstemmed Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing
title_short Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing
title_sort assessing and advancing the safety of crispr-cas tools: from dna to rna editing
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9838544/
https://www.ncbi.nlm.nih.gov/pubmed/36639728
http://dx.doi.org/10.1038/s41467-023-35886-6
work_keys_str_mv AT taojianli assessingandadvancingthesafetyofcrisprcastoolsfromdnatornaediting
AT bauerdaniele assessingandadvancingthesafetyofcrisprcastoolsfromdnatornaediting
AT chiarleroberto assessingandadvancingthesafetyofcrisprcastoolsfromdnatornaediting

Ejemplares similares